Clinical Trial Update: Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the impact of reactogenicity on quality of life after administration of GSK's HZ/su vaccine (GSK1437173A) in adults aged 50+; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• HZ/su vaccine GSK1437173A (HZ/su vaccine GSK1437173A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2018-10-16